Bio-Path Holdings Inc.

12/11/2024 | Press release | Distributed by Public on 12/11/2024 06:25

Bio Path Holdings Outlines Rationale for Development of BP1001 A as Potential Treatment for Obesity in Type 2 Diabetes Patients